Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

parnell technologies pty ltd - carprofen - oral syrup - carprofen anti-inflammatory-nonsteroidal active 10.0 mg/ml - musculoskeletal system - dog | bitch | castrate | puppy - anti-inflammatory agent | antipyretic | bone soreness | bruising | bursitis | inflammatory rheumatic arthrit | joint disease | ligament sprains | muscle soreness | osteoarthritis | platelet activity | rheumatism | sprains | strains | tendon sprains | traumatic swelling

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

norbrook laboratories australia pty limited - carprofen - oral tablet - carprofen anti-inflammatory-nonsteroidal active 20.0 mg/tb - musculoskeletal system - dog | bitch | castrate | puppy - anti-inflammatory agent | antipyretic | bone soreness | bruising | bursitis | inflammatory rheumatic arthrit | joint disease | ligament sprains | muscle soreness | osteoarthritis | platelet activity | rheumatism | sprains | strains | tendon sprains | traumatic swelling

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - carprofen - parenteral liquid/solution/suspension - carprofen anti-inflammatory-nonsteroidal active 50.0 mg/ml - analgesic+musculoskeletal - cat | dog | horse | bitch | castrate | cat - queen | cat - tom | colt | donkey | endurance horse | filly | foal | gelding | high - analgesic | anti-inflammatory agent | non steroidal | antipyretic | bone soreness | bruising | bursitis | colic | inflammatory rheumatic arthrit | joint disease | ligament sprains | muscle relaxant | muscle soreness | osteoarthritis | platelet activity | rheumatism | sedative | spasmolytic | sprains | strains | tendon sprains | traumatic swelling

Israel - English - Ministry of Health

novartis israel ltd - secukinumab - solution for injection - secukinumab 150 mg/ml - secukinumab - - plaque psoriasis: cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. - paediatric plaque psoriasis: cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy. - psoriatic arthritis: cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous disease modifying anti rheumatic drug (dmard) therapy has been inadequate. - axial spondyloarthritis (axspa) : •ankylosing spondylitis (as, radiographic axial spondyloarthritis) cosentyx is indicated for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy. •non-radiographic axial spondyloarthritis (nr-axspa) cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs (nsaids). - juvenile idiopathic arthritis (jia) •enthesitis-related arthritis (era) cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active enthesitisrelated arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. •juvenile psoriatic arthritis (jpsa) cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.hidradenitis suppurativa (hs)cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic hs therapy

Israel - English - Ministry of Health

neopharm (israel)1996 ltd - adalimumab - solution for injection - adalimumab 50 mg/ml - adalimumab - • rheumatoid arthritis: idacio in combination with methotrexate is indicated for:- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate.- the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. idacio can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. adalimumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function, when given in combination with methotrexate.• axial spondyloarthritis:-ankylosing spondylitis (as): idacio is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.-axial spondyloarthritis without radiographic evidence of as: idacio is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as, but with objective signs of inflammation by radiological and/or laboratory tests including mri and serum crp levels, who have had an inadequate response to, or are intolerant to, non-steroidal anti-inflammatory drugs.• psoriatic arthritis: idacio is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti rheumatic drug therapy has been inadequate. adalimumab has been shown to reduce the rate of progression of peripheral joint damage as measured by x-ray in patients with polyarticular symmetrical subtypes of the disease and to improve physical function.• psoriasis: idacio is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy.• hidradenitis suppurativa (hs): idacio is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adult patients with an inadequate response to conventional systemic hs therapy.• crohn’s disease: idacio is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active crohn’s disease who have had an inadequate response to conventional therapy. idacio is indicated for reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab. • ulcerative colitis: idacio is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. • uveitis:idacio is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate.• intestinal behcet's disease: idacio is indicated for the treatment of intestinal behcet’s disease in patients who have had an inadequate response to conventional therapy.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

vetoquinol australia pty ltd - tolfenamic acid - parenteral liquid/solution/suspension - tolfenamic acid anti-inflammatory-non-steroid active 40.0 mg/ml - musculoskeletal system - cat | dog | bitch | castrate | cat - queen | cat - tom | kitten | puppy - anti-inflammatory agent | antipyretic | bone soreness | bruising | bursitis | inflammatory rheumatic arthrit | joint disease | ligament sprains | muscle soreness | osteoarthritis | platelet activity | rheumatism | sprains | strains | tendon sprains | traumatic swelling

Israel - English - Ministry of Health

pfizer pharmaceuticals israel ltd - etanercept - powder and solvent for solution for injection - etanercept 25 mg/vial - etanercept - etanercept - rheumatoid arthritis:- enbrel is indicated for the treatment of active rhematoid arthritis in adults when the response to disease-modifying antirheumatic drugs (dmards) including methotrexate (unless contraindicated) has been inadequate. enbrel can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone. - reducing signs and symptoms and inhibiting the progression of structural damage in patients with moderately to severely active rheumatoid arthritis.enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function.* psoriatic arthritistreatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. enbrel has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by x ray in patients with polyarticular symmetrical subtypes of the disease. * plaque psoriasis treatment of adults patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.* paediatric plaque psoriasis treatment of chronic severe plaque psoriasis in children and adolescents from the age of 6 years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.* juvenile idiopathic arthritis- treatment of polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. - treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate.- treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy.*axial spondyloarthritis- ankylosing spondylitis(as)treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.- non-radiographic axial spondyloarthritistreatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence, who have had an inadequate response to nonsteroidal anti-inflammatory drugs (nsaids).

Israel - English - Ministry of Health

pfizer pharmaceuticals israel ltd - etanercept - solution for injection - etanercept 50 mg/ml - etanercept - etanercept - * rheumatoid arthritis:- enbrel is indicated for the treatment of active rhematoid arthritis in adults when the response to disease-modifying antirheumatic drugs (dmards) including methotrexate (unless contraindicated) has been inadequate.. enbrel can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone. - reducing signs and symptoms and inhibiting the progression of structural damage in patients with moderately to severely active rheumatoid arthritis.enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function.* psoriatic arthritistreatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. enbrel has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by x ray in patients with polyarticular symmetrical subtypes of the disease. * plaque psoriasis treatment of adults patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.* paediatric plaque psoriasis treatment of chronic severe plaque psoriasis in children and adolescents from the age of 6 years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.* juvenile idiopathic arthritis- treatment of polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. - treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate.treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy. enbrel has not been studied in children aged less than 2 years.* axial spondyloarthritis- ankylosing spondylitis(as)treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.- non-radiographic axial spondyloarthritistreatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence, who have had an inadequate response to nonsteroidal anti-inflammatory drugs (nsaids)

Israel - English - Ministry of Health

pfizer pharmaceuticals israel ltd - etanercept - solution for injection - etanercept 50 mg/ml - etanercept - etanercept - * rheumatoid arthritis:- enbrel is indicated for the treatment of active rhematoid arthritis in adults when the response to disease-modifying antirheumatic drugs (dmards) including methotrexate (unless contraindicated) has been inadequate.. enbrel can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone. - reducing signs and symptoms and inhibiting the progression of structural damage in patients with moderately to severely active rheumatoid arthritis.enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function.* psoriatic arthritistreatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. enbrel has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by x ray in patients with polyarticular symmetrical subtypes of the disease. * plaque psoriasis treatment of adults patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.* paediatric plaque psoriasis treatment of chronic severe plaque psoriasis in children and adolescents from the age of 6 years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.* juvenile idiopathic arthritis- treatment of polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. - treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate.treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy.enbrel has not been studied in children aged less than 2 years.* axial spondyloarthritis- ankylosing spondylitis(as)treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.- non-radiographic axial spondyloarthritistreatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence, who have had an inadequate response to nonsteroidal anti-inflammatory drugs (nsaids).

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - omeprazole, quantity: 20 mg - tablet, enteric coated - excipient ingredients: purified talc; hypromellose; iron oxide red; carnauba wax; sodium stearylfumarate; iron oxide yellow; titanium dioxide; sodium stearate; sodium lauryl sulfate; hypromellose acetate succinate; sodium starch glycollate; propylene glycol; lactose monohydrate; triethyl citrate; monoethanolamine - gastroesophageal reflux disease (gord). symptomatic gord: the relief of heartburn and other symptoms associated with gord. . erosive oesophagitis: the treatment and prevention of relapse. . peptic ulcers: the treatment of duodenal and gastric ulcer. . combination therapy for the treatment of peptic ulcer disease associated with h. pylori infection. . the treatment of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs. . the prevention of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs in patients assessed as being at high risk of gastroduodenal ulcer or complications of gastroduodenal ulcer. . long-term prevention of relapse in gastric and duodenal ulceration, in patients proven to be h. pylori negative, or in whom eradication is inappropriate, e.g. the elderly or ineffective. . zollinger-ellison syndrome: the treatment of zollinger-ellison syndrome